FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2050524315> ?p ?o ?g. }

• W2050524315 endingPage "510" @default.
• W2050524315 startingPage "505" @default.
• W2050524315 abstract "Objective The aim of the study was to evaluate somatostatin receptor expression in non–131I-concentrating metastatic differentiated thyroid carcinoma by 68Ga-DOTATATE PET-CT/99mTc-HYNIC-TOC scintigraphy and to determine the feasibility of 177Lu-DOTATATE (therapeutic analog) therapy in cases with positive 68Ga-DOTATATE PET-CT/99mTc-HYNIC-TOC scintigraphy. Methods In this research study, 19 patients diagnosed with differentiated thyroid carcinoma with non–iodine-concentrating metastasis with elevated serum thyroglobulin levels, attending thyroid outpatient department for follow-up, underwent 68Ga-DOTATATE PET-CT/99mTc-HYNIC-TOC scan for the evaluation of positivity of somatostatin receptor (SSTR). Based on the visual grading, SSTR-positive lesions were graded into 4 categories (grades I-IV) in comparison with the hepatic uptake on the scan. Patients with grades III and IV uptake in lesions (equal to or more than hepatic uptake on scan) were scheduled for 177Lu-DOTATATE administration. Posttherapy 177Lu-DOTATATE scan was undertaken during discharge from the isolation ward. Results Of the 19 patients studied, 12 patients (63%) showed SSTR-positive lesion expression demonstrating uptake ranging from grade I-IV, and 7 patients (37%) did not demonstrate any tracer uptake. On a lesion-specific analysis, of the total 57 metastatic lesions, 4 lesions (7%) demonstrated grade I tracer uptake, 18 lesions (31%) grade II (less than liver), 2 lesions (3.5%) grade III (equal to liver uptake), and 1 lesion showed grade IV uptake (more than liver). Interestingly, an elevated serum chromogranin A level was documented in 3 of the patients with grades III and IV tumor uptake. A comparison of 68Ga-DOTATATE PET-CT and 99mTc-HYNIC-TOC in 4 patients who underwent both the scans demonstrated no significant differences in the tracer concentration in the metastatic lesions in any of the patients on visual grading. Based on the criterion of high tracer uptake and the patient consent, finally 2 of 3 patients were treated with 177Lu-DOTATATE. On follow-up after 3 months, a significant fall in serum thyroglobulin level was noted in one of the patients, and the other patient was lost to follow-up. Conclusions Avid expression of the SSTR on 68Ga-DOTATATE PET-CT/99mTc-HYNIC-TOC scintigraphy in non–131I-concentrating metastatic differentiated thyroid cancer is observed in a relatively low fraction of patients that could favor the feasibility of 177Lu-DOTATATE therapy. Although seen in a small fraction, taking into account that no treatment exists in this group, somatostatin receptor–targeted imaging can be an alternative diagnostic modality in the therapeutic decision making with peptide receptor radionuclide therapy and monitoring. The documentation of elevated serum chromogranin A level in 3 patients with intense tracer uptake could suggest a possible neuroendocrine differentiation in the affected tissues leading to the expression of chromogranin A along with SSTR-avid expression. This observation needs to be explored in future studies. No definite conclusions can be drawn on the therapeutic efficacy of the 177Lu-DOTATATE therapy in this group at present, and more prospective research is required in this area." @default.
• W2050524315 created "2016-06-24" @default.
• W2050524315 creator A5016925714 @default.
• W2050524315 creator A5054315303 @default.
• W2050524315 creator A5062180890 @default.
• W2050524315 date "2014-06-01" @default.
• W2050524315 modified "2023-09-27" @default.
• W2050524315 title "Somatostatin Receptor Imaging in Non–131I-Avid Metastatic Differentiated Thyroid Carcinoma for Determining the Feasibility of Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE" @default.
• W2050524315 cites W1526861962 @default.
• W2050524315 cites W1584743295 @default.
• W2050524315 cites W1966732161 @default.
• W2050524315 cites W2001050314 @default.
• W2050524315 cites W2003968902 @default.
• W2050524315 cites W2015998907 @default.
• W2050524315 cites W2025378414 @default.
• W2050524315 cites W2033670397 @default.
• W2050524315 cites W2050035799 @default.
• W2050524315 cites W2060305272 @default.
• W2050524315 cites W2070929260 @default.
• W2050524315 cites W2090257199 @default.
• W2050524315 cites W2090382285 @default.
• W2050524315 cites W2103509522 @default.
• W2050524315 cites W2108461872 @default.
• W2050524315 cites W2116542352 @default.
• W2050524315 cites W2118986295 @default.
• W2050524315 cites W2140207212 @default.
• W2050524315 cites W2151499798 @default.
• W2050524315 cites W2917068635 @default.
• W2050524315 cites W4211107646 @default.
• W2050524315 doi "https://doi.org/10.1097/rlu.0000000000000429" @default.
• W2050524315 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24662668" @default.
• W2050524315 hasPublicationYear "2014" @default.
• W2050524315 type Work @default.
• W2050524315 sameAs 2050524315 @default.
• W2050524315 citedByCount "26" @default.
• W2050524315 countsByYear W20505243152014 @default.
• W2050524315 countsByYear W20505243152015 @default.
• W2050524315 countsByYear W20505243152016 @default.
• W2050524315 countsByYear W20505243152017 @default.
• W2050524315 countsByYear W20505243152018 @default.
• W2050524315 countsByYear W20505243152019 @default.
• W2050524315 countsByYear W20505243152020 @default.
• W2050524315 countsByYear W20505243152021 @default.
• W2050524315 countsByYear W20505243152022 @default.
• W2050524315 countsByYear W20505243152023 @default.
• W2050524315 crossrefType "journal-article" @default.
• W2050524315 hasAuthorship W2050524315A5016925714 @default.
• W2050524315 hasAuthorship W2050524315A5054315303 @default.
• W2050524315 hasAuthorship W2050524315A5062180890 @default.
• W2050524315 hasConcept C126322002 @default.
• W2050524315 hasConcept C126838900 @default.
• W2050524315 hasConcept C142724271 @default.
• W2050524315 hasConcept C2776297358 @default.
• W2050524315 hasConcept C2779902710 @default.
• W2050524315 hasConcept C2781156865 @default.
• W2050524315 hasConcept C2989005 @default.
• W2050524315 hasConcept C2993294228 @default.
• W2050524315 hasConcept C2993559085 @default.
• W2050524315 hasConcept C526584372 @default.
• W2050524315 hasConcept C71924100 @default.
• W2050524315 hasConcept C80115893 @default.
• W2050524315 hasConceptScore W2050524315C126322002 @default.
• W2050524315 hasConceptScore W2050524315C126838900 @default.
• W2050524315 hasConceptScore W2050524315C142724271 @default.
• W2050524315 hasConceptScore W2050524315C2776297358 @default.
• W2050524315 hasConceptScore W2050524315C2779902710 @default.
• W2050524315 hasConceptScore W2050524315C2781156865 @default.
• W2050524315 hasConceptScore W2050524315C2989005 @default.
• W2050524315 hasConceptScore W2050524315C2993294228 @default.
• W2050524315 hasConceptScore W2050524315C2993559085 @default.
• W2050524315 hasConceptScore W2050524315C526584372 @default.
• W2050524315 hasConceptScore W2050524315C71924100 @default.
• W2050524315 hasConceptScore W2050524315C80115893 @default.
• W2050524315 hasIssue "6" @default.
• W2050524315 hasLocation W20505243151 @default.
• W2050524315 hasLocation W20505243152 @default.
• W2050524315 hasOpenAccess W2050524315 @default.
• W2050524315 hasPrimaryLocation W20505243151 @default.
• W2050524315 hasRelatedWork W1806859398 @default.
• W2050524315 hasRelatedWork W2023296765 @default.
• W2050524315 hasRelatedWork W2080318597 @default.
• W2050524315 hasRelatedWork W2093693472 @default.
• W2050524315 hasRelatedWork W2143345249 @default.
• W2050524315 hasRelatedWork W2381365220 @default.
• W2050524315 hasRelatedWork W2386686465 @default.
• W2050524315 hasRelatedWork W2744424417 @default.
• W2050524315 hasRelatedWork W2947522592 @default.
• W2050524315 hasRelatedWork W4378903809 @default.
• W2050524315 hasVolume "39" @default.
• W2050524315 isParatext "false" @default.
• W2050524315 isRetracted "false" @default.
• W2050524315 magId "2050524315" @default.
• W2050524315 workType "article" @default.